Sapna Srivastava

Sapna Srivastava is the current Director at SQZ Biotech. Sapna has also previously served as Interim Chief Financial Officer at eGenesis, Inc. from March 2021 to October 2021. Prior to that, they were a Board Member at VelosBio from October 2020 to December 2020.

Srivastava began their career as a Biotechnology Analyst at Morgan Stanley from January 2004 to December 2009. Sapna then transitioned to Goldman Sachs, where they served as a Biotechnology Stock Analyst from January 2010 to December 2012. After Goldman Sachs, they became the Chief Financial and Strategy Officer at Intellia Therapeutics, Inc. from April 2015 to December 2016. Most recently, they served as the Chief Financial and Strategy Officer at Abide Therapeutics from September 2017 to January 2019 before joining the team at SQZ Biotech.

Sapna Srivastava received their Doctor of Philosophy (Ph.D.) from New York University.